Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||-31%|
|Revenue Growth (QoQ)|
|Held by Institutions %||13%|
|1 Day Vol Adjusted Return||0.1|
|1 Month Vol Adjusted Return||-6.6|
|3 Month Vol Adjusted Return||-20.5|
|6 Month Vol Adjusted Return||-23.6|
|20 Days SMA Price ZScore||-1.0|
|50 Days SMA Price ZScore||-1.2|
|12 -26 Days PPO||-5.3|
|1 Month Average Short Volume Ratio||35.1|
|1 Day Volume Change ZScore||-0.3|
|1 Month Daily Vol||1.4|
GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.
Burberry CFO Julie Brown was named the next finance chief at GSK, joining CEO Emma Walmsley.
Pharmaceutical firm GSK hired the finance chief of British luxury fashion group Burberry to lead its finances after the recent spinoff of its consumer-health business.
GSK plc (NYSE: GSK) has appointed Julie Brown as its first-ever female chief financial officer to succeed Iain Mackay. Mackay, 60, will retire next year after serving as GSK's finance chief for nearly four years. Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023. Ms. Brown currently serves as Chief Operating and Financial Officer at the luxury fashion brand Burberry Group plc (O
British consumer goods giant Unilever PLC (NYSE: UL) Chief Executive Officer Alan Jope intends to retire in 2023 end. The decision comes after the CEO came under severe criticism over a failed takeover bid of drugmaker GSK Plc's (NYSE: GSK) consumer health unit worth £50 billion ($53 billion), Bloomberg reported. GSK rejected Unilever's bid and ended up spinning off its consumer healthcare business into an independently-traded public company, named Haleon. The company reported an underlying EPS
After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.
British drugmaker GSK plc has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019, the report added. On Friday, Burberry announced that its finance chief Julie Brown will step down in April 2023 after more than five years in the role.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.